|
|
GEO help: Mouse over screen elements for information. |
|
Status |
Public on Apr 19, 2016 |
Title |
Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanomas |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Therapeutic targeting of BRAFV600Eand of MEK has shown a significant impact on progression-free and overall survival in advanced melanoma, but only a fraction of patients benefit from these treatments, suggesting that additional signaling pathways involved in melanoma growth/survival need to be identified. To this end, we used whole genome microarray analysis to identify differentially expressed genes in a set of neoplastic clones, isolated from a single melanoma metastasis, and characterized by mututally exclusive expression of BRAFV600E or NRASQ61R. By this approach we identified two genes, SEMA6A and Mical-1 belonging to the semaphorin-plexin signaling pathway and higly expressed, at mRNA and protein level, in BRAF-mutant neoplastic clones. Real-time PCR, Western blot analysis and immunohistochemistry confirmed the preferential expression of SEMA-6A and Mical-1 in BRAFV600E neoplastic cells from melanoma clones, primary and metastatic cell lines and tissue sections from melanoma lesions. SEMA6A depletion, by specific RNA-interference experiments, led to cytoskeletal remodeling, loss of stress fibers, generation of actin-rich protrusion, and cell death, whereas SEMA6A overexpression, in NRASQ61R clones, promoted invasiveness. Mical-1 depletion, by siRNA, in BRAFV600E melanomas, did not alter the actin cytoskeleton organization but caused a strong NDR phosphorylation and NDR-dependent apoptosis. Overall, these results suggest that the SEMA and MICAL pathways contribute to promote survival of BRAFV600E melanomas.
|
|
|
Overall design |
The human melanoma cell lines Me 4405, Me26635, Me665/2, Me10538; clones 2/33; 2/21; 2/4; 2/17; 2/14; 2/59 were established in our laboratory from a surgical specimens. Cells were routinely maintained in RPMI medium 1640 supplemented with 10% FBS and 2 mM glutamine. Cells were maintained at 37°C in a water-saturated atmosphere of 5% CO2 in air. 6x106 cells were seeded in 75 cm2 flasks; after 72h Me 4405 and Me26635 were untreated or treated with fotemustine at 300 μmol/L for 6 hours. Each treatment or combination was performed in triplicate. The cells were collected and RNA extracted.
|
|
|
Contributor(s) |
De Cecco L, Anichini A |
Citation(s) |
25576923 |
Submission date |
Jun 03, 2014 |
Last update date |
Aug 16, 2018 |
Contact name |
Loris De Cecco |
E-mail(s) |
loris.dececco@istitutotumori.mi.it
|
Organization name |
IRCSS Istituto Nazionale Tumori
|
Street address |
via Venezian 1
|
City |
Milan |
ZIP/Postal code |
20133 |
Country |
Italy |
|
|
Platforms (1) |
GPL6947 |
Illumina HumanHT-12 V3.0 expression beadchip |
|
Samples (36)
|
|
Relations |
BioProject |
PRJNA251555 |
Supplementary file |
Size |
Download |
File type/resource |
GSE58199_RAW.tar |
6.2 Mb |
(http)(custom) |
TAR |
GSE58199_non-normalized_data.txt.gz |
11.2 Mb |
(ftp)(http) |
TXT |
Processed data included within Sample table |
|
|
|
|
|